2nd line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) скачать в хорошем качестве

2nd line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

In this video, Prof Efrat Dotan discusses second-line chemotherapy options for metastatic pancreatic ductal adenocarcinoma (PDAC) and how earlier treatments have an impact on treatment sequence. Data from key clinical trials such as CONKO-003, PANCREOX-1 and NAPOLI-1 are discussed, and the role of targeted therapy is considered. Summary points Cytotoxic chemotherapy remains the cornerstone of systemic therapy for advanced or metastatic pancreatic cancer The choice of second-line therapy depends on which treatments the patient has received in the 1st line setting and therefore which options are left available to them Treatment selection depends on several other factors, including patients' performance status and co-morbidities. These should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens Treatment strategies can be implemented to manage toxicities associated with the different chemotherapy regimens to enable a patient to stay on treatment for optimal efficacy Key clinical takeaways Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed at an advanced, incurable stage due to non-specific symptoms and has an extremely poor prognosis Systemic chemotherapy is the standard treatment for metastatic PDAC but molecularly targeted treatments and immunotherapies may have a role for specific patients Treatment selection depends on several factors, including patients' performance status and co-morbidities. These should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens Treatment strategies can be implemented to manage toxicities associated with the different chemotherapy regimens to enable a patient to stay on treatment for optimal efficacy Download the accompanying slides here: https://cor2ed.com/gi-connect/program... Follow us on social media: LinkedIn:   / giconnect   X: https://x.com/giconnectInfo This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Education Grant from Ipsen USA. This video was developed by https://cor2ed.com/ Published April 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.